COGT - Cogent Biosciences, Inc.
NEXT EARNINGS:
May 12, 2026
EPS Est: $-0.53
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$45.00
DETAILS
HIGH:
$60.00
LOW:
$20.00
MEDIAN:
$48.00
CONSENSUS:
$45.00
UPSIDE:
14.85%
Market Cap:
6.01B
Volume:
1,517,870
Avg Volume:
2,287,223
52 Week Range:
3.72-43.73
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.47
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
205
IPO Date:
2018-03-29
EPS (TTM):
-2.55
P/E Ratio:
-7.30
Revenue (TTM):
N/A
Total Assets:
937.61M
Total Debt:
253.15M
Cash & Equiv:
312.01M
Rev Growth (5Y):
-100.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-38.2%
Debt/Equity:
0.40
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-17 | $-0.55 | $-0.51 | -7.8% | — | — | — |
| 2025-11-07 | $-0.50 | $-0.54 | +7.4% | — | — | — |
| 2025-08-05 | $-0.53 | $-0.55 | +3.6% | — | — | — |
| 2025-05-06 | $-0.52 | $-0.56 | +7.1% | — | — | — |
| 2025-02-25 | $-0.09 | $-0.59 | +84.7% | — | — | — |
| 2024-11-12 | $-0.64 | $-0.55 | -16.4% | — | — | — |
| 2024-08-06 | $-0.59 | $-0.55 | -7.3% | — | — | — |
| 2024-05-07 | $-0.62 | $-0.50 | -24.0% | — | — | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Net Income | (328.94M) | (255.86M) | (192.41M) | (140.24M) | (72.27M) | (74.81M) | (30.27M) | (34.53M) | (25.49M) | (18.12M) | (6.59M) |
| EPS | -2.55 | -2.46 | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| Total Assets | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M | 250.92M | 49.42M | 85.93M | 49.12M | 75.55M | 94.77M |
| Total Debt | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M | 5.21M | 6.03M | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 312.01M | 98.17M | 53.23M | 139.89M | 219.68M | 242.19M | 37.42M | 55.67M | 28.27M | 41.32M | 90.48M |
| Operating Cash Flow | (264.44M) | (207.79M) | (153.62M) | (118.64M) | (58.76M) | (35.85M) | (41.51M) | (32.49M) | (25.84M) | (18.64M) | 17.72M |
| Free Cash Flow | (266.00M) | (208.36M) | (156.42M) | (125.50M) | (60.48M) | (35.85M) | (41.55M) | (33.04M) | (26.75M) | (21.95M) | 15.72M |
| FCF per Share | -3.93 | -2.01 | -1.96 | -2.14 | -1.56 | -3.24 | -5.45 | -5.31 | -3.62 | -3.75 | 2.69 |
| Book Value | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M | 234.67M | 31.76M | 60.23M | 28.30M | 52.39M | 69.52M |
| Cash & ST Investments | 900.76M | 287.08M | 265.71M | 259.28M | 219.68M | 242.19M | 37.42M | 78.59M | 40.96M | 68.51M | 90.48M |
| ROC Equity | -0.52 | -1.00 | -0.75 | -0.55 | -0.34 | -0.32 | -0.95 | -0.57 | -0.90 | -0.35 | -0.09 |